AstraZeneca turns COPD inhaler into asthma growth engine as Trixeo wins broader EU label
European regulators have approved AstraZeneca’s Trixeo Aerosphere for uncontrolled asthma from age 12 regardless of recent exacerbation history, potentially widening a respiratory franchise that generated $699 million in first-half 2026 sales.